CCTA characterization of coronary atherosclerosis diffuseness and focality using FFR-CT and plaque burden: results from the PRECISE trial.

Eur J RadiolAug 22, 2026 (epub)
Clinical ResearchCardiology

Ruurt A Jukema, Pamela S Douglas, John K Khoo et al.

✦ AI-curated · Sources linked

In 30 seconds

The PRECISE trial examined coronary atherosclerosis characteristics in 737 patients with stable suspected coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) and fractional flow reserve computed tomography (FFR-CT). The study found that total plaque volume was highest in patients with combined focal and diffuse CAD (DIFFOC) at 262 mm³, and revascularization was performed in about 51% of focal CAD patients.

Key findings

  • Total plaque volume was highest in DIFFOC patients at 262 [175-504] mm³.
  • Revascularization rates were 51% for focal CAD and 49% for combined focal and diffuse CAD.
  • Typical angina was reported more frequently in focal CAD patients (p = 0.04).
  • Only 2% of patients with <50% stenosis underwent revascularization.

Why it matters

Understanding the characteristics of CAD, including diffuseness and focality, can help clinicians better assess patient management and treatment strategies, particularly regarding revascularization decisions.

Source

PubMed · PMID 42659899

Published in Eur J Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.